PepGen (PEPG) Projected to Announce Earnings on Wednesday

Key Points

• PepGen is expected to report Q3 2026 results before market open on November 11, with analysts forecasting a loss of $0.27 per share. The company’s earnings call is scheduled for November 12 at 9:30 a.m. ET.
• In its previous quarter, PepGen reported a loss of $0.26 per share, beating analysts’ estimate of a $0.28 loss. Analysts expect losses of $1.11 per share for the current fiscal year and $1.27 for the next.
• The stock recently traded at $2.45, below its 50-day and 200-day moving averages. Analysts’ average rating is “Moderate Buy,” with an average price target of $11.40.

PepGen (NASDAQ:PEPG - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. On average, analysts expect PepGen to post ($1.11) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

PepGen Price Performance

Shares of PEPG stock traded down $0.01 during trading hours on Wednesday, reaching $2.45. 64,352 shares of the company were exchanged, compared to its average volume of 1,023,380. The stock's fifty day moving average is $2.72 and its two-hundred day moving average is $3.04. The company has a market cap of $169.48 million, a price-to-earnings ratio of -1.91 and a beta of 2.02. PepGen has a fifty-two week low of $1.31 and a fifty-two week high of $7.80.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Weiss Ratings upgraded PepGen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 22nd. HC Wainwright reissued a "buy" rating on shares of PepGen in a research report on Wednesday, September 9th. Finally, Wall Street Zen downgraded shares of PepGen from a "hold" rating to a "sell" rating in a research note on Saturday, October 10th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $11.40.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company's technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen's platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.